Horizon Discovery Group plc Block Listing Application (7395L)

TIDMHZD

RNS Number : 7395L

Horizon Discovery Group plc

24 July 2017

24 July 2017

Horizon Discovery Group plc

Block Listing Application

The Company today announces that an application has been made to the London Stock Exchange for a block admission of 3,000,000 new ordinary shares of 1p each in the Capital of the Company ("New Ordinary Shares") to be admitted to trading on AIM (the "Block Admission"). It is expected that Admission will occur on 26 July 2017.

These New Ordinary Shares shall be issued and allotted from time to time pursuant to the exercise of share options under the following share schemes:

-- Horizon Discovery Limited Enterprise Management Incentive Share Option Scheme (up to 1,398,000 shares)

   --      Horizon Discovery Group plc Long Term Incentive Plan (up to 1,392,000 shares) 
   --      Horizon Discovery 2014 Sharesave Scheme (up to 110,000 shares) 
   --      Horizon Discovery Group plc US Employee Stock Purchase Plan (up to 100,000 shares) 

The new ordinary shares, when issued, will rank pari passu with the existing shares of the Company.

Following admission, the Company's issued share capital remains unchanged at 96,571,853. The Company will make six-monthly announcements of the utilisation of the Block Admission, in line with its obligations under AIM Rule 29.

For further information, please contact:

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Susan Stuart / Matthew Neal / Melissa Gardiner

Tel: [phone]

Email: [e-mail]

Numis Securities Limited (Broker and NOMAD)

Michael Meade / Freddie Barnfield

Tel: [phone]

About Horizon Discovery Group plc www.horizondiscovery.com

Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health.

Horizon's core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN, CRISPR and Transposon) able to alter almost any gene sequence in human or mammalian cell-lines.

Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and animal models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizon's commercial offering has been adopted by over 1,600 unique research organisations in over 50 countries as well as in the Company's own R&D pipeline to support a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalised basis.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD".

This information is provided by RNS

The company news service from the London Stock Exchange

END

ALSLIFITDAILFID

(END) Dow Jones Newswires

July 24, 2017 02:00 ET (06:00 GMT)